Katrine Bosley, former CEO of Avila Therapeutics, states that drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Her preferred strategy would be two-way, iterative partnerships bringing together big drugmakers' experience with small biotechs' innovation.
Supply Chains Are Orderly. Biotech Innovation Is Messy | Xconomy
I was intrigued by the concept of an “innovation supply chain” for biotech raised in last week’s Xconomy discussion with Noubar Afeyan of Flagship Ventures
Google+: View post on Google+